Loading
A phase 3 trial of Copper Cu 64 PSMA I&T in prostate cancer, run by Curium US LLC, active and no longer recruiting.
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06235151 by Curium US LLC, with 439 participants enrolled, started 2024-04-01 and due to reach its primary completion in 2026-09. Interventions recorded: Copper Cu 64 PSMA I&T.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.